Search results for "terase"

showing 10 items of 446 documents

Current state of clinical and morphological features in human NCL.

2004

The neuronal ceroid lipofuscinoses (NCL) are large group of autosomal recessive lysosomal storage disorders with both enzymatic deficiency and structural protein dysfunction. Previously, diagnosis of (NCL) was based on age at onset clinicopathological (C‐P) findings described 4 forms, classified as infantile (INCL) (2), late‐infantile (LINCL) (5), juvenile (JNCL) (6), and adult (ANCL) most patients with NCL have progressive ocular and cerebral dysfunvtion, including cognitive/motor dysfunction and uncontrolled seizures. After reviewing 520 patients with NCL, we found that about 104 (20%) did not fit this classification of NCL With further research, 4 additional forms have been recognized: F…

AdultPathologymedicine.medical_specialtymedicine.disease_causeArticlePathology and Forensic MedicineEpilepsyNeuronal Ceroid-LipofuscinosesGenotypemedicineHumansPalmitoyl protein thioesteraseAge of OnsetChildInclusion BodiesMutationbiologyTripeptidyl-Peptidase 1General NeurosciencePPT1Infantmedicine.diseasePhenotypeCLN8Child PreschoolMutationbiology.proteinNeurology (clinical)Age of onsetBrain pathology (Zurich, Switzerland)
researchProduct

A quantitative study of the pancuronium antagonism at the motor endplate in human organophosphorus intoxication

1995

Nine patients with organophosphorus (OP) intoxication developing neuromuscular transmission defects were given pancuronium 1, 2, or 4 mg intravenously (IV). Thirteen patient controls with hypoxic encephalopathy received similar dosages. The responses were monitored electrophysiologically using single and repetitive nerve stimulation (20 and 50 Hz). In OP patients, pancuronium did not alter the amplitude of the single CMAP, whereas its repetitive discharges were reduced. Severe neuromuscular blocks were reversed only partially by pancuronium 4 mg. In less severe blocks, 1 and 2 mg resulted in marked improvement. In the patient controls, pancuronium 4 mg induced a severe neuromuscular block b…

AdultTime FactorsPhysiologymedicine.medical_treatmentNeuromuscular transmissionAction PotentialsElectromyographyMotor EndplateSynaptic TransmissionNeuromuscular junctionCellular and Molecular Neurosciencechemistry.chemical_compoundOrganophosphate PoisoningPhysiology (medical)medicineHumansPancuroniumRepetitive nerve stimulationAntidoteNeuromuscular BlockadeMovement DisordersDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryNeuromuscular DiseasesAcetylcholinesteraseElectric Stimulationmedicine.anatomical_structurechemistryAnesthesiaInjections IntravenousToxicityAcetylcholinesteraseNeurology (clinical)businessMuscle & Nerve
researchProduct

Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5)

2011

The clitoris contributes to the normal female sexual response cycle. A significance of cyclic guanosine monophosphate (GMP) has been assumed in the control of clitoral vascular smooth muscle. As only a few investigations on the physiology of the vascular and non-vascular clitoral tissue have been carried out, knowledge on the mechanisms controlling this particular female genital organ is still vague. It has been suggested that human clitoral corpus cavernosum smooth muscle is regulated by nitric oxide (NO)/cyclic GMP and related key enzymes, such as NO synthases (NOSs) and the phosphodiesterase type 5 (PDE5). The present study evaluated in the human clitoris, by means of immunohistochemistr…

Adultmedicine.medical_specialtyVascular smooth muscleStromal cellAdolescentNitric Oxide Synthase Type IIIUrologyClitorisBiologyEndothelial NOSSecond Messenger SystemsClitorisNitric oxideYoung Adultchemistry.chemical_compoundInternal medicineCyclic GMP-Dependent Protein KinasesmedicineHumansVimentinProtein kinase ACyclic GMPCyclic guanosine monophosphateCyclic Nucleotide Phosphodiesterases Type 5Cyclic Nucleotide Phosphodiesterases Type 2Immunohistochemistrymedicine.anatomical_structureEndocrinologychemistrycGMP-specific phosphodiesterase type 5FemaleInternational Journal of Impotence Research
researchProduct

A53T-Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice

2010

BACKGROUND: Parkinson's disease (PD), the second most frequent neurodegenerative disorder at old age, can be caused by elevated expression or the A53T missense mutation of the presynaptic protein alpha-synuclein (SNCA). PD is characterized pathologically by the preferential vulnerability of the dopaminergic nigrostriatal projection neurons. METHODOLOGY/PRINCIPAL FINDINGS: Here, we used two mouse lines overexpressing human A53T-SNCA and studied striatal dysfunction in the absence of neurodegeneration to understand early disease mechanisms. To characterize the progression, we employed young adult as well as old mice. Analysis of striatal neurotransmitter content demonstrated that dopamine (DA…

AgingDopaminelcsh:MedicineMicechemistry.chemical_compoundHomer Scaffolding ProteinsReceptor Cannabinoid CB1lcsh:ScienceLong-term depressionNeurotransmitterChromatography High Pressure LiquidIn Situ Hybridization FluorescenceOligonucleotide Array Sequence AnalysisMice KnockoutNeuronal PlasticityMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionDopaminergicNeurodegenerationGenetics and Genomics/Gene ExpressionElectrophysiologyalpha-SynucleinResearch ArticleRadioimmunoprecipitation Assaymedicine.medical_specialtyNeuronal Calcium-Sensor ProteinsHOMER1Substantia nigraNeurotransmissionBiologyNeurological DisordersInternal medicinemedicineAnimalsHumansddc:610Cyclic Nucleotide Phosphodiesterases Type 7Activating Transcription Factor 2lcsh:RNeuropeptidesmedicine.diseaseMolecular biologyCorpus StriatumMice Mutant StrainsEndocrinologyGenetics and Genomics/Disease ModelschemistrySynaptic plasticitylcsh:QCarrier ProteinsPLoS ONE
researchProduct

Choline is a Selective Agonist of α7 Nicotinic Acetylcholine Receptors in the Rat Brain Neurons

1998

In the present study, we demonstrate that choline, a precursor of acetylcholine (ACh) and a product of acetylcholine hydrolysis by acetylcholinesterase (AChE), acts as an efficient and relatively selective agonist of alpha7-containing nicotinic acetylcholine receptors (nAChR) in neurons cultured from the rat hippocampus, olfactory bulb and thalamus as well as in PC12 cells. Choline was able to activate postsynaptic and presynaptic alpha7 nAChRs, with the latter action resulting in the release of other neurotransmitters. Although choline was approximately one order of magnitude less potent than ACh (EC50 of 1.6 mM for choline and 0.13 mM for ACh), it acted as a full agonist at alpha7 nAChRs.…

AgonistN-MethylaspartatePatch-Clamp Techniquesmedicine.drug_classNicotinic AntagonistsMecamylaminePharmacologyHippocampusPC12 Cellscomplex mixturesCholineRats Sprague-DawleyMethylamineschemistry.chemical_compoundThalamusPostsynaptic potentialExcitatory Amino Acid AgonistsmedicineAnimalsCholineNicotinic AgonistsNootropic AgentsAcetylcholine receptorNeuronsGeneral NeuroscienceBungarotoxinsOlfactory BulbCholine acetyltransferaseAcetylcholinesteraseAcetylcholineRatsNicotinic agonistnervous systemchemistryBiochemistryDimethylphenylpiperazinium IodideAcetylcholinemedicine.drugEuropean Journal of Neuroscience
researchProduct

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

2000

Impairment of the central cholinergic system has a pivotal role in the cognitive decline observed in patients with Alzheimer’s disease (AD). One of the most prominent cholinergic deficits is the reduced number of nicotinic acetylcholine receptors (nAChR) in the brain. Since these receptors are important for memory and learning, enhancing nicotinic neurotransmission is a promising treatment strategy for AD. The two most common approaches to correcting these cholinergic deficits are to increase the synaptic availability of acetylcholine (ACh) by inhibiting acetylcholinesterase (AChE), or to mimic the effects of ACh (nicotinic agonists) by acting directly on nicotinic receptors. Clinical studi…

Agonistmedicine.drug_classGalantamineCognitive NeuroscienceAllosteric regulationCholinergic AgentsPharmacologyReceptors NicotinicAcetylcholinesteraseSynaptic TransmissionPsychiatry and Mental healthchemistry.chemical_compoundNicotinic agonistchemistryAlzheimer DiseaseGalantaminemedicineCholinergicHumansGeriatrics and GerontologyCognitive declineNeuroscienceAcetylcholinemedicine.drugDementia and geriatric cognitive disorders
researchProduct

Postnatal alterations of the inhibitory synaptic responses recorded from cortical pyramidal neurons in the Lis1/sLis1 mutant mouse

2006

Mutations in the mouse Lis1 gene produce severe alterations in the developing cortex. We have examined some electrophysiological responses of cortical pyramidal neurons during the early postnatal development of Lis/sLis1 mutant mice. In P7 and P30 Lis1/sLis1 neurons we detected a lower frequency and slower decay phase of mIPSCs, and at P30 the mIPSCs amplitude and the action potential duration were reduced. Zolpidem (an agonist of GABAA receptors containing the alpha1 subunit) neither modified the amplitude nor the decay time of mIPSCs at P7 in Lis1/sLis1 neurons, whereas it increased the decay time at P30. The levels of GABAA receptor alpha1 subunit mRNA were reduced in the Lis1/sLis1 brai…

Agonistmedicine.medical_specialtyZolpidemPyridinesmedicine.drug_classAction PotentialsIn Vitro TechniquesBiologyInhibitory postsynaptic potentialMiceCellular and Molecular NeuroscienceInternal medicinemedicineAnimalsReceptorGABA AgonistsMolecular BiologyCerebral CortexReverse Transcriptase Polymerase Chain ReactionGABAA receptorPyramidal CellsAge FactorsGene Expression Regulation DevelopmentalCell BiologyElectric StimulationMice Mutant StrainsCortex (botany)ZolpidemElectrophysiologymedicine.anatomical_structureEndocrinologyAnimals NewbornInhibitory Postsynaptic Potentialsnervous systemCerebral cortex1-Alkyl-2-acetylglycerophosphocholine EsteraseMicrotubule-Associated Proteinsmedicine.drugMolecular and Cellular Neuroscience
researchProduct

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

2003

Galantamine (Reminyl), an approved treatment for Alzheimer's disease (AD), is a potent allosteric potentiating ligand (APL) of human alpha 3 beta 4, alpha 4 beta 2, and alpha 6 beta 4 nicotinic receptors (nAChRs), and of the chicken/mouse chimeric alpha 7/5-hydroxytryptamine3 receptor, as was shown by whole-cell patch-clamp studies of human embryonic kidney-293 cells stably expressing a single nAChR subtype. Galantamine potentiates agonist responses of the four nAChR subtypes studied in the same window of concentrations (i.e., 0.1-1 microM), which correlates with the cerebrospinal fluid concentration of the drug at the recommended daily dosage of 16 to 24 mg. At concentrations10 microM, gal…

Agonistmedicine.medical_specialtymedicine.drug_classRecombinant Fusion ProteinsAllosteric regulationPhenylcarbamatesRivastigminePharmacologyReceptors NicotinicMiceAllosteric RegulationPiperidinesInternal medicineMuscarinic acetylcholine receptormedicineGalantamineAnimalsHumansDonepezilReceptorTrichlorfonCells CulturedPharmacologyNeuronsChemistryGalantamineLigand (biochemistry)Receptors MuscarinicEndocrinologyNicotinic agonistIndansTacrineMolecular MedicineCholinergicCarbamatesCholinesterase Inhibitorsmedicine.drugThe Journal of pharmacology and experimental therapeutics
researchProduct

Metabolite profile and in vitro activities of Phagnalon saxatile (L.) Cass. relevant to treatment of Alzheimer’s disease

2009

The present study describes for the first time the in vitro properties (inhibition of NO production and anticholinesterase) of Phagnalon saxatile (L.) Cass. (Asteraceae). The methanolic extract showed antioxidant activity that was measured by DPPH assay and beta-carotene bleaching test. The same extract inhibited NO production in the murine monocytic macrophage cell line RAW 264.7. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition was assessed by modifications of Ellman's method. Purification of the MeOH extract of P. saxatile allowed the isolation of phenolic compounds. Among them, the compounds that most effectively inhibited lipopolysaccharide-induced NO production …

AntioxidantDPPHmedicine.medical_treatmentMetaboliteAsteraceaePharmacologyNitric OxideInhibition of NO productionCell LineMicechemistry.chemical_compoundPhagnalon saxatileAlzheimer DiseaseDrug DiscoverymedicineCaffeic acidAnimalsHumansSettore BIO/15 - Biologia FarmaceuticaIC50ButyrylcholinesterasePharmacologyPlant Extractsinhibition of NO production Alzheimer's diseaseSettore CHIM/06 - Chimica OrganicaGeneral MedicineAcetylcholinesterasePhenolic compoundsAlzheimers diseasechemistryBiochemistryPhagnalon saxatile asteraceae phenolic compoundButyrylcholinesteraseAcetylcholinesteraseCholinesterase InhibitorsLuteolinJournal of Enzyme Inhibition and Medicinal Chemistry
researchProduct

Vascular Activity of (-)-Anonaine, (-)-Roemerine and (-)-Pukateine, Three Natural 6a(R)-1,2-Methylenedioxyaporphines with Different Affinities for α1…

2004

We have studied the mechanism of action of three 6a( R)-1,2-methylenedioxyaporphines as vasorelaxant compounds. The alkaloids assayed showed different affinities for the three human cloned alpha (1)-adrenoceptor (AR) subtypes stably expressed in rat-1 fibroblasts, showing lower affinity for alpha(1B)-AR with regard to the alpha(1A)- or alpha(1D)-subtypes. These three natural compounds are more potent inhibitors of [ (3)H]-prazosin binding than of [ (3)H]-diltiazem binding to rat cerebral cortical membranes. As all these alkaloids inhibited noradrenaline (NA)-induced [ (3)H]-inositol phosphate formation in cerebral cortex and rat tail artery, they may be safely viewed as alpha (1)-AR antagon…

AporphinesPhosphodiesterase InhibitorsStereochemistryPharmaceutical ScienceAorta ThoracicDioxolesBiologyMuscle Smooth VascularAnalytical ChemistryHydroxylationchemistry.chemical_compoundAlkaloidsDrug DiscoverymedicineAnonaineAnimalsHumansAporphineRats WistarBinding sitePukateineCerebral CortexPharmacologyPlants MedicinalVoltage-dependent calcium channelAlkaloidOrganic ChemistryArteriesReceptors Adrenergic alphaIsoquinolinesRatsComplementary and alternative medicineMechanism of actionchemistryMolecular MedicineFemaleCalcium Channelsmedicine.symptomDrugs Chinese HerbalPhytotherapyPlanta Medica
researchProduct